Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OmniGuide's flexible laser tech:

This article was originally published in Clinica

Executive Summary

OmniGuide has CE-marked for sale in Europe its flexible CO2 laser fibres for use in minimally-invasive surgery. Its OtoBeam and BeamPath systems, which are already approved in the US, can now be sold in all countries that accept the CE-mark, said the Cambridge, Massachusetts firm. Most CO2 lasers have a rigid articulating arm that limits the surgeon to procedures where a "line-of-sight" from outside the patient's body is possible, the firm claimed. The OmniGuide fibre, which is fitted to this existing base of CO2 laser systems, allows physicians to place the fibre into the patient's body under endoscopic guidance to treat lesions within the skull base, airway and larynx.

You may also be interested in...



RECOVERY Coronavirus Study ‘Will Attract Global Players To UK’

A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.

Warning Letter Roundup & Recap – 8 April 2020

Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.

Expanding The Tent: Improving Trial Participation Among Under-Represented Patient Populations

The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.

Topics

UsernamePublicRestriction

Register

MT049351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel